Latest Breaking News On - Sun ophthalmic cequa - Page 1 : comparemela.com

Aldeyra Therapeutics reported that its reproxalap hit the mark in the Phase III Tranquility-2 study for dry eye disease. The drug showed statistical superiority for its two primary endpoints.

United statesJacobr langAldeyra therapeuticsreportedNovarti xiidraAbbvie allergan restasisPtoddc bradyCathleen mccabeEye health americaEye associates in sarasotaDrug administrationEye associatesEye healthNew drug applicationAssociated eye careOyster pointSun ophthalmic cequa